Cargando…

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients

C-X3-C motif chemokine ligand 1 (CX3CL1)/fractalkine is a chemokine released after cleavage by two metalloproteases, ADAM metallopeptidase domain 10 (ADAM10) and ADAM metallopeptidase domain 17 (ADAM17), involved in inflammation and angiogenesis in the cancer microenvironment. The role of the CX3CL1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchica, Valentina, Toscani, Denise, Corcione, Anna, Bolzoni, Marina, Storti, Paola, Vescovini, Rosanna, Ferretti, Elisa, Dalla Palma, Benedetta, Vicario, Emanuela, Accardi, Fabrizio, Mancini, Cristina, Martella, Eugenia, Ribatti, Domenico, Vacca, Angelo, Pistoia, Vito, Giuliani, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469019/ https://www.ncbi.nlm.nih.gov/pubmed/30845779 http://dx.doi.org/10.3390/cancers11030321

Ejemplares similares

Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies
por: Ferretti, Elisa, et al.
Publicado: (2014)

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
por: Marchica, Valentina, et al.
Publicado: (2020)

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
por: Costa, Federica, et al.
Publicado: (2017)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Fractalkine/CX3CL1 in Neoplastic Processes
por: Korbecki, Jan, et al.
Publicado: (2020)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts
por: Bolzoni, Marina, et al.
Publicado: (2017)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
por: Accardi, Fabrizio, et al.
Publicado: (2015)

EHMTI-0062. Expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the trigeminal ganglia: implications for craniofacial nociception
por: Gazerani, P, et al.
Publicado: (2014)

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
por: Storti, Paola, et al.
Publicado: (2022)

CX(3)CR1 Is Expressed by Human B Lymphocytes and Meditates CX(3)CL1 Driven Chemotaxis of Tonsil Centrocytes
por: Corcione, Anna, et al.
Publicado: (2009)

The Chemokine CX3CL1 (Fractalkine) and its Receptor CX3CR1: Occurrence and Potential Role in Osteoarthritis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2014)

Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
por: Imai, Toshio, et al.
Publicado: (2016)

Fractalkine Signalling (CX(3)CL1/CX(3)CR1 Axis) as an Emerging Target in Coronary Artery Disease
por: Loh, Shu Xian, et al.
Publicado: (2023)

Correction: CX(3)CR1 Is Expressed by Human B Lymphocytes and Mediates CX(3)CL1 Driven Chemotaxis of Tonsil Centrocytes
por: Corcione, Anna, et al.
Publicado: (2010)

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
por: Accardi, Fabrizio, et al.
Publicado: (2018)

Fractalkine (CX3CL1) and Its Receptor CX3CR1 May Contribute to Increased Angiogenesis in Diabetic Placenta
por: Szukiewicz, Dariusz, et al.
Publicado: (2013)

CX3CL1 (Fractalkine) Protein Expression in Normal and Degenerating Mouse Retina: In Vivo Studies
por: Zieger, Marina, et al.
Publicado: (2014)

Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma
por: Upton, Nadine, et al.
Publicado: (2017)

Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis
por: Wojdasiewicz, Piotr, et al.
Publicado: (2020)

Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
por: Cormican, Sarah, et al.
Publicado: (2021)

Elevated Expression of Fractalkine (CX3CL1) and Fractalkine Receptor (CX3CR1) in the Dorsal Root Ganglia and Spinal Cord in Experimental Autoimmune Encephalomyelitis: Implications in Multiple Sclerosis-Induced Neuropathic Pain
por: Zhu, Wenjun, et al.
Publicado: (2013)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
por: Storti, Paola, et al.
Publicado: (2020)

Fractalkine/CX3CR1 signaling during neuropathic pain
por: Clark, Anna K., et al.
Publicado: (2014)

Fractalkine/CX(3)CR(1) Pathway in Neuropathic Pain: An Update
por: Silva, Rita, et al.
Publicado: (2021)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Corrigendum to “Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis”
por: Wojdasiewicz, Piotr, et al.
Publicado: (2020)

Pathological Role of Fractalkine/CX3CL1 in Rheumatic Diseases: A Unique Chemokine with Multiple Functions
por: Jones, Brian, et al.
Publicado: (2012)

CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver
por: Bourd-Boittin, Katia, et al.
Publicado: (2009)

Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients
por: Cimato, Thomas R, et al.
Publicado: (2014)

Fractalkine (CX3CL1), a new factor protecting β-cells against TNFα
por: Rutti, Sabine, et al.
Publicado: (2014)

Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation
por: Lauro, Clotilde, et al.
Publicado: (2015)

CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway
por: Liu, Peng, et al.
Publicado: (2018)

Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis
por: Celesti, G, et al.
Publicado: (2013)

P850: THE HUMORAL AND CELLULAR RESPONSE TO SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA AND PRE-MALIGNANT MONOCLONAL GAMMOPATHIES: IMPACT OF OMICRON VARIANT
por: Storti, P., et al.
Publicado: (2022)

CX(3)CL1 (fractalkine) and CX(3)CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin
por: Sunnemark, Dan, et al.
Publicado: (2005)

CX(3)CL1 (fractalkine) and its receptor CX(3)CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin
por: Staumont-Sallé, Delphine, et al.
Publicado: (2014)

Association of CX3CR1 Gene Polymorphisms with Fractalkine, Fractalkine Receptor, and C-Reactive Protein Levels in Patients with Kidney Failure
por: Woźny, Łukasz, et al.
Publicado: (2021)

Neuronal autophagy aggravates microglial inflammatory injury by downregulating CX3CL1/fractalkine after ischemic stroke
por: He, Hong-Yun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4c6n8bqjha8p7aekcopos8ngju